The company just confirmed that there have been zero Inavir stockpiling sales since its launch.
I forgot they need the prevention indication before they get access to stockpiling orders.
So, if we focus on the Japanese seasonal market in the Dec Qtr (ie leave out Tamiflu stockpiling sales):
* Inavir sales of 1.7 billion
* Tamiflu sales of 1.1 billion
= Inavir had 61% of the seasonal market in the Dec Qtr.
All before Relenza sales reported this week.
- Forums
- ASX - By Stock
- BTA
- inavir royalties
inavir royalties, page-20
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online